Articles On EMvision Medical Devices (ASX:EMV)

Highlights ASX200 sees a slight upward trend with sector gains. Penny stocks offer unique growth opportunities. Focus on penny stocks with strong financial health. The Australian market recently closed with a mixed performance,...

There are several ASX biotech companies developing drugs to treat complex neurological conditions Global neurological disorder drugs market size set to reach US$149.17 billion by 2032 Petra Capital’s Tanushree Jain says neurological disord...

ASX health stocks break losing streak, up 1.78% over past week, while the broader market rises 2.01% Nanosonics receives US FDA De Novo clearance for its flexible endoscope cleaning system Coris Sigma’s full-year FY25 results as a stand al...

TBI awareness month highlights need for better care ASX companies roll out devices to tackle TBI head-on From portable scanners to life-changing tech, TBI solutions are evolving   March is Traumatic Brain Injury (TBI) Awareness Month, a...

EMVision Medical Devices (ASX: EMV) has completed aeromedical retrieval environment testing of its First Responder proof-of-concept (PoC) device to treat rural patients with stroke and traumatic brain injury (TBI). The company used the worl...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, Tylah Tully gives the skinny on EMVsion Medical Devices’ (ASX:EMV)  latest advancement of its ‘First Responder’ proof-of-concept device,...

Emvision to launch remote stroke detection trial It’s a tricky market but biotechs are raising funds Imugene wins FDA fast-track status for cancer program   Ahead of a wider trial, Emvision Medical Devices (ASX:EMV) has taken to the air w...

  EMVision is transitioning from R&D stage to commercialisation with its portable brain scanners to diagnose stroke First 60 minutes after a stroke is known as ‘the golden hour’ and is particularly critical for positive outcomes Pivot...

  EMVision is moving from R&D stage to commercialisation with its portable brain scanner to detect stroke First 60 minutes after a stroke is known as ‘the golden hour’ and can determine outcomes Pivotal trial for US FDA approval of EMU...

Highlights  Ceretas secures $1 million to further develop its breakthrough ultrasound therapy for dementia.  Backed by leading investors and strong philanthropic support, the company progresses toward clinical trials.  The technology...

Highlights Australian penny stocks show growth potential amid market volatility EMVision (EMV), Praemium (PPS), and Wagners Holding (WGN) demonstrate strong financial profiles The Reserve Bank's upcoming rate decision creates a dynami...

The ASX200 has been up 0.25% at 8,505 points. Industrials has been the strongest performing sector, up 1.6%, followed by Financials, up 1.07%, and Staples, up 0.92%. IT has been the worst-performing sector, down 1.63, followed by Heal...

It’s starting to look like a flat Wednesday, with Aussie futures now pointing to a near-unnoticeable 0.03% drop for the bourse at open today. We finally got Federal Reserve chairman Jerome Powell’s latest stance on cuts in the U.S. overn...

Having lodged their paperwork, companies including EBR Systems, Artyra and Orthocell await crucial FDA approval The agency has improved its communications with applicants, which avoids nasty surprises Applicants are doing the commercial gr...

ASX 200 drops as gold, iron ore and energy stocks struggle Paladin shares plunge after cutting uranium output forecast Australian business confidence hits two-year high amid easing inflation   The ASX 200 index slipped by 0.13% on Tuesday...

Emvision expects to release trial results for its Emu stroke-detection device in November Syntara’s rare blood cancer program gathers pace Actinogen says 25 patients have been treated in its 200-candidate Alzheimer’s disease study   Quart...

In this interview Dale Gillham and small cap company director Rod North discuss what to look for in microcap stocks and what place they should have in an investor’s portfolio. They discuss success stories, risk vs reward, and, the challe...

Nyrada to launch phase I first-in-human trial after passing preclinical safety studies Neuren Pharmaceuticals ‘mini me’ Percheron seeks funds for rare disease program Another win for Pro Medicus, this time locally   Nyrada (ASX:NYR) share...

Curvebeam’s innovative products are revolutionising cone beam CT imaging The company’s HiRise offers weight-bearing CT scans directly to a surgeon’s office The enhanced HiRise has recently received FDA clearance   The medical devices segm...

Founder-led medical technology company EMVision (ASX: EMV) has today unveiled its proof of concept device for a backpack-sized brain scanner to be used by first responders, which if successfully commercialised would allow paramedics to scan...

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

Stage 2 interim data from a pre-validation trial by EMVision Medical Devices (ASX: EMV) has confirmed the positive performance of neurodiagnostic artificial intelligence (AI) algorithms in the diagnosis of suspected haemorrhagic or ischaemi...

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

    ASX 200 set to rise Monday, following New York’s rally US traders optimistic after Michigan survey, easing inflation concerns Approval for Ether ETFs opens door for Blackrock, VanEck, and Ark 21Shares   The ASX 200 is poised to rebou...

Australian company EMVision Medical Devices (ASX:EMV) has secured a strategic $15.28 million investment via a placement to the long-standing investor in the company, Keysight Technologies.

EMvision receives strategic investment from NYSE-listed firm Radiopharm doses first patient in Phase 1 pancreatic cancer trial   EMVision receives investment from NYSE-listed Keysight EMVision Medical Devices (ASX:EMV) soared as high as 1...

  ASX to open lower, tracking Wall Street Fed member sees rate cuts this year as inflation data looms Bitcoin pops to over US$60k, with more catalysts to come   The ASX is poised to open lower on Thursday in line with losses on Wall Stre...

So much for a small rise on the market today. Instead, the ASX200 closed down about three quarters (.76) per cent. Real estate stocks proved the biggest drag, down just over one and a quarter of a per cent, while IT was the only sector t...

The ASX200 has been trading down more than .4 per of a per cent today.    Information technology is the only sector in the green, adding nearly a per cent, while consumer discretionary is the poorest performer so far, down nearly 1.2 per...

EMVision (ASX:EMV) reveals the name of its inaugural point-of-care brain scanner device, ’emu’, at the RSNA 2023 conference In parallel, the company has fully recruited 150 suspected stroke patients for stage two of its multi-site clinic...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

EMVision Medical Devices (ASX:EMV) assembles an advanced 28-antenna prototype for its second-generation helmet scanner The ultra-lightweight helmet scanner is designed for use in road and air ambulance settings An ethics submission fo...

Recce Pharma moves forward to stronger dose in Phase 1/2 trial EMV is bench testing its 2nd Gen ultra-light weight helmet scanner   Recce Pharma moves forward to higher dosage Synthetic anti-infectives producer, Recce Pharmaceuticals (ASX...

Paradigm Biopharma set to submit application to TGA EMVision uses artificial intelligence simulation   Paradigm to submit TGA application after successful trial Paradigm Biopharmaceuticals (ASX:PAR) jumped 13% this morning after reporting...

Shares to rise for third day in a row Wall Street lifted after comments from Fed official Gold and oil stocks continued to climb on the back of Middle East fallout   Aussie shares are poised to rise for the third day in a row today. At 8a...

Medical devices offer faster route to commercialisation than drugs How newly listed Curvebeam AI aims to grab market share Stockhead reached out to Curvebeam AI CEO, Greg Brown   Despite the recent rally, the ASX Healthcare Index (XHJ) is...

Stroke has long been recognised as being among Australia’s most costly disease groups.  It occurs when a blood vessel supplying blood to the brain either suddenly becomes blocked or ruptures and begins to bleed which can result in part of t...

EMVision Medical Devices (EMV) reports all three of its clinical trial sites are now enrolling The Princess Alexandra Hospital sites in Brisbane are now live with the company reporting “excellent” maintenance of enrolment levels The c...

EMVision Medical Devices (ASX:EMV), which is developing portable brain imaging for stroke, has announced the third and final clinical trial site for its Gen 1 device, enabling faster detection and diagnosis of stroke.

Shares to open flat after the Fed bumped rates another 25bp Google, Microsoft and Meta reported earnings The word AI was mentioned over 1,000 times in the earnings reports   Local shares are set to open flat on Thursday after a mixed sess...

EMVision Medical Devices (ASX:EMV) has received a cash progress payment of $1,750,000 under its Modern Manufacturing Initiative grant award.

EMVision (ASX: EMV) founder Scott Kirkland will step into the CEO role from 1 July, succeeding Dr Ron Weinberger who joined the portable brain scanner company five years ago after a 13-year stint in leadership roles at Nanosonics (ASX: NAN)...

EMVision Medical Devices (EMV) activates stage two of the multi-site trial for its first-generation portable brain scanner Stage two will see EMV enrol 150 acute stroke and stroke-mimic patients across major medical centres in Australia...

The ASX is set to rise on Monday on a relief rally Another chipmaker, Marvell, surges 32pc Shaq O’Neal served court papers for doing FTX ads   Aussie shares are set to rally on Monday after the White House and Republicans reached a tentat...

EMVision Medical Devices (EMV) completes the enrolment of 30 healthy volunteers into its stage one clinical trial for its brain scanning tech The company is looking to test its portable EMVision brain scanner device, which obtains images...

EMVision Medical Devices (EMV) completes enrolment of around half the 30 participants required for its stage one clinical trial for stroke monitoring The company told investors its pre-validation phase of the clinical trial is on schedul...

EMVision Medical Devices (EMV) begins the multi-centre clinical trial of its brain scanner deviceFollowing user training at the Liverpool Hospital in Sydney, enrolment of a planned 30 healthy volunteers has begunMoving forward, stage two of...

Little Green Pharma gets ethics approval to commence Phase 3 trial EMVision has commenced a clinical trial   Little Green Pharma to start Phase 3 trial Cannabis company Little Green Pharma (ASX:LGP) has secured Human Research Ethics Appro...

The ASX will open lower on Wednesday, tracking Wall Street Apple has lost US$165 billion of market cap in the last few days Fed Chair Jerome Powell expected to speak later tonight   The ASX is set to open lower on Wednesday, tracking the...

EMV Medical Devices delivered its first portable brain scanner Firebrick Pharma gets patent in Australia Antisense to progress on clinical trial EMVision delivers first brain scanner EMVision Medical Devices (ASX:EMV) jumped 7% after anno...